• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Antibiotics: An International Journal >Antibiotics in the clinical pipeline in October 2019
【24h】

Antibiotics in the clinical pipeline in October 2019

机译：2019年10月临床管道的抗生素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The development of new and effective antibacterial drugs to treat multi-drug resistant (MDR) bacteria, especially Gram-negative (G-ve) pathogens, is acknowledged as one of the world's most pressing health issues; however, the discovery and development of new, nontoxic antibacterials is not a straightforward scientific task, which is compounded by a challenging economic model. This review lists the antibacterials, beta-lactamase/beta-lactam inhibitor (BLI) combinations, and monoclonal antibodies (mAbs) first launched around the world since 2009 and details the seven new antibiotics and two new beta-lactam/BLI combinations launched since 2016. The development status, mode of action, spectra of activity, lead source, and administration route for the 44 small molecule antibacterials, eight beta-lactamase/BLI combinations, and one antibody drug conjugate (ADC) being evaluated in worldwide clinical trials at the end of October 2019 are described. Compounds discontinued from clinical development since 2016 and new antibacterial pharmacophores are also reviewed. There has been an increase in the number of early stage clinical candidates, which has been fueled by antibiotic-focused funding agencies; however, there is still a significant gap in the pipeline for the development of new antibacterials with activity against beta-metallolactamases, orally administered with broad spectrum G-ve activity, and new treatments for MDR Acinetobacter and gonorrhea.
机译：新增抗菌药物以治疗多药物抗菌（MDR）细菌，尤其是革兰氏阴性（G-VE）病原体的发展被认为是世界上最紧迫的健康问题之一;然而，发现和开发新的无毒抗菌不是一个直接的科学任务，这是一个充满挑战的经济模型复杂化。本综述列出了自2009年以来首次在世界各地推出的抗菌剂，β-内酰胺酶/β-内酰胺抑制剂（BLI）组合和单克隆抗体（MAB），并详细了解自2016年以来推出的七种新的抗生素和两种新的β-内酰胺/ BLI组合。44个小分子抗菌剂，八种β-内酰胺酶/ BLI组合的44个小分子抗菌剂，八种β-内酰胺酶/ BLI组合和在全球临床试验中进行评估描述了2019年10月底。此后临床发展中停止的化合物还审查了新的抗菌药程治。早期临床候选人的数量增加，已被抗生素的融资机构推动;然而，管道中仍然存在显着的差距，用于开发具有对β-金属酰胺蛋白酶的活性的新抗菌，口服施用广谱G-VE活性，以及​​用于MDR致癌杆菌和淋病的新处理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号